VanGln-1: A Protein Involved in Multiple Cellular Processes and Potential Drug Targets

Target Name: VANGL1

NCBI ID: G81839

VANGL1

VanGln-1: A Protein Involved in Multiple Cellular Processes and Potential Drug Targets

VanGln-1 (LPP2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the serine/threonine protein kinase (SMPK) family and is involved in a variety of cellular processes, including cell signaling, cell survival, and tissue repair.

One of the unique features of VanGln-1 is its ability to interact with several different protein substrates, including casein kinase (CK) 3,4, and 5, as well as the protein kinase A1 (PKA1). This interacting ability makes VanGln- 1 a potential drug target, as it can be targeted by small molecules that can inhibit or activate these protein interactions.

In addition to its potential as a drug target, VanGln-1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because its expression is often increased in these types of diseases, and may be a Useful indicator of the severity or progression of these conditions.

One of the ways that VanGln-1 is involved in disease is its role in the regulation of cell death. In neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, VanGln-1 has been shown to contribute to the progression of neurodegeneration by promoting the survival of damaged neurons and glial cells. This may be because VanGln-1 helps to regulate the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of neurodegeneration.

Another way that VanGln-1 is involved in disease is its role in tissue repair. In diseases such as diabetes, wounds, and radiation-induced tissue damage, VanGln-1 has been shown to play a role in promoting the repair of damaged tissue by regulates the production of pro-inflammatory cytokines. This may be because VanGln-1 helps to prevent the excessive production of these cytokines, which can contribute to tissue inflammation and the development of chronic diseases.

In addition to its role in disease, VanGln-1 is also a potential drug target because of its unique structure and the fact that it is expressed in multiple tissues. This makes it a challenging target, as it is difficult to predict the effects of a drug on a protein that is expressed in multiple tissues and is involved in multiple cellular processes. However, there is ongoing research into the potential targeting of VanGln-1 as a drug target, both alone and in combination with other treatments.

Overall, VanGln-1 is a protein that is involved in a variety of cellular processes and has been implicated in the development and progression of several diseases. As a potential drug target and biomarker, it is an attractive target for researchers to explore as a means of developing new treatments for a variety of conditions.

Protein Name: VANGL Planar Cell Polarity Protein 1

The "VANGL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VANGL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets